First Nebraska Trust Co Acquires 7,373 Shares of AbbVie Inc. $ABBV

First Nebraska Trust Co acquired a new stake in AbbVie Inc. (NYSE:ABBV) during the third quarter, Holdings Channel.com reports. The institutional investor acquired 7,373 shares of the company’s stock, valued at approximately $1,929,000.

Other hedge funds have also recently bought and sold shares of the company. Evergreen Private Wealth LLC increased its position in AbbVie by 3.3% in the third quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company’s stock worth $285,000 after purchasing an additional 35 shares during the period. Torray Investment Partners LLC raised its holdings in AbbVie by 0.9% during the 3rd quarter. Torray Investment Partners LLC now owns 83,376 shares of the company’s stock worth $21,810,000 after purchasing an additional 774 shares during the last quarter. Factory Mutual Insurance Co. lifted its position in AbbVie by 6.2% during the 3rd quarter. Factory Mutual Insurance Co. now owns 197,798 shares of the company’s stock valued at $51,742,000 after purchasing an additional 11,548 shares during the period. CrossGen Wealth LLC lifted its position in AbbVie by 9.0% during the 3rd quarter. CrossGen Wealth LLC now owns 6,519 shares of the company’s stock valued at $1,705,000 after purchasing an additional 536 shares during the period. Finally, VCI Wealth Management LLC lifted its position in AbbVie by 36.9% during the 3rd quarter. VCI Wealth Management LLC now owns 12,506 shares of the company’s stock valued at $3,271,000 after purchasing an additional 3,370 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Citigroup raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Barclays boosted their price target on shares of AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 21st. Cantor Fitzgerald increased their price objective on shares of AbbVie from $290.00 to $325.00 and gave the company an “overweight” rating in a report on Monday. Piper Sandler raised their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Finally, Rothschild & Co Redburn lifted their target price on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $296.88.

AbbVie Trading Down 1.0%

NYSE:ABBV opened at $285.88 on Wednesday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $298.74. The business’s 50-day moving average price is $270.23 and its two-hundred day moving average price is $237.89. The firm has a market capitalization of $505.09 billion, a price-to-earnings ratio of 49.20, a PEG ratio of 1.31 and a beta of 0.20.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The firm had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a negative return on equity of 435.41% and a net margin of 15.67%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.86 earnings per share. Sell-side analysts predict that AbbVie Inc. will post 14.00 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a $1.82 dividend. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio is 119.10%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its 2026 outlook, projecting EPS of $13.95–$13.99 and revenue of $67.8 billion, both slightly above consensus at the midpoint. Its latest quarter also beat analyst estimates, with revenue up 10.3% year over year. Q3 earnings outlook and pipeline progress
• Positive Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million, signaling continued commitment to research and development. Reuters: Oxford R&D expansion
• Positive Sentiment: The company expanded its migraine-drug partnership with Brise in a deal potentially worth up to $757 million, adding to its pipeline prospects. AbbVie-Brise license deal
• Positive Sentiment: Several analysts raised their price targets after the quarterly results, reflecting confidence in AbbVie’s growth transition. Analyst target increases
• Negative Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 is below the $3.89 consensus, despite revenue guidance of $18.4 billion topping expectations. That earnings shortfall could temper the otherwise stronger full-year outlook.
• Negative Sentiment: After a strong run, valuation concerns remain: one recent analysis described the shares as stretched and questioned how much further growth from Skyrizi and pipeline deals is already reflected in the price. Valuation and upside analysis

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by insiders.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.